Drug
Emtricitabine and tenofovir disoproxil fumarate
Emtricitabine and tenofovir disoproxil fumarate is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (50.0%)
Phase 41 (50.0%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_4
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
NCT01285050
completed
PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color
NCT02367807
completedphase_2
Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)
NCT00551018
Clinical Trials (3)
Showing 3 of 3 trials
NCT01285050Phase 4
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
NCT02367807
PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color
NCT00551018Phase 2
Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3